Immunogenicity and immunoprotection of porcine circovirus type 2 (PCV2) Cap protein displayed by Lactococcus lactis

Li, Pengcheng; Qiao, Xuwen; Zheng, Qi; Hou, Jingbo

doi:10.1016/j.vaccine.2015.09.007

Cited by 35 publications

(24 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, the relevant research has not yet been conducted; therefore, the effectiveness of PiCV vaccines in combatting YPDS has not yet been confirmed. The hypothesis that a subunit vaccine against PiCV could be effective in preventing YPDS is based on studies where similar vaccines have been used for controlling porcine circovirus infections in pigs (Zhang et al 2015b;Zhu et al 2016;Li et al 2016). Attempts have also been made to immunize parrots with the recombinant capsid protein of the psittacine circovirus, but the efficacy of the vaccine was not confirmed (Bonne et al 2009).…”

Section: Diagnosis Treatment and Preventionmentioning

confidence: 99%

The epidemiology, molecular characterization and clinical pathology of circovirus infections in pigeons – current knowledge

Stenzel

Koncicki

2017

Veterinary Quarterly

View full text Add to dashboard Cite

The first cases of circovirus infections in pigeons were documented less than 25 years ago. Since then, circovirus infections have been reported on nearly all continents. The specificity of pigeon breeding defies biosecurity principles, which could be the reason for the high prevalence of PiCV infections. PiCV infections in pigeons lead to atrophy of immune system organs and lymphocyte apoptosis. Infected birds could be more susceptible to infections of the respiratory and digestive tract. PiCV has been associated with the young pigeon disease syndrome (YPDS). PiCVs are characterized by high levels of genetic diversity due to frequent point mutations, recombination processes in the PiCV genome and positive selection. Genetic recombinations and positive selection play the key role in the evolution of PiCV. A protocol for culturing PiCV under laboratory conditions has not yet been developed, and traditional vaccines against the infection are not available. Recombinant capsid proteins for detecting anti-PiCV antibodies have been obtained, and these antigens can be used in the production of diagnostic tests and subunit vaccines against PiCV infections. However, YPDS has complex etiology, and it remains unknown whether immunization against PiCV alone will contribute to effective control of YPDS.

show abstract

Section: Diagnosis Treatment and Preventionmentioning

confidence: 99%

The epidemiology, molecular characterization and clinical pathology of circovirus infections in pigeons – current knowledge

Stenzel

Koncicki

2017

Veterinary Quarterly

View full text Add to dashboard Cite

show abstract

“…GEM particles can also bind to different antigen proteins in the same particles to develop multivalent vaccines [42]. The system has successfully displayed a variety of heterologous proteins from pathogens, showing strong antigen-specific immune responses with parenteral vaccination or mucosal vaccination, including viruses, bacteria, and parasites [38,[43][44][45][46]. In our study, the results suggest that the RBD protein of MERS-CoV displayed on the GEM particles could induce strong humoral and cellular immune response even when the dose is as low as 1 µg.…”

Section: Discussionmentioning

confidence: 99%

Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice

Yan

Huang

et al. 2020

Viruses

View full text Add to dashboard Cite

Middle East respiratory syndrome (MERS) is an acute, high-mortality-rate, severe infectious disease caused by an emerging MERS coronavirus (MERS-CoV) that causes severe respiratory diseases. The continuous spread and great pandemic potential of MERS-CoV make it necessarily important to develop effective vaccines. We previously demonstrated that the application of Gram-positive enhancer matrix (GEM) particles as a bacterial vector displaying the MERS-CoV receptor-binding domain (RBD) is a very promising MERS vaccine candidate that is capable of producing potential neutralization antibodies. We have also used the rabies virus (RV) as a viral vector to design a recombinant vaccine by expressing the MERS-CoV S1 (spike) protein on the surface of the RV. In this study, we compared the immunological efficacy of the vaccine candidates in BALB/c mice in terms of the levels of humoral and cellular immune responses. The results show that the rabies virus vector-based vaccine can induce remarkably earlier antibody response and higher levels of cellular immunity than the GEM particles vector. However, the GEM particles vector-based vaccine candidate can induce remarkably higher antibody response, even at a very low dose of 1 µg. These results indicate that vaccines constructed using different vaccine vector platforms for the same pathogen have different rates and trends in humoral and cellular immune responses in the same animal model. This discovery not only provides more alternative vaccine development platforms for MERS-CoV vaccine development, but also provides a theoretical basis for our future selection of vaccine vector platforms for other specific pathogens.

show abstract

“…In detail, QK-LysM, as a fusion protein, was loaded onto GEM particles by the LysM domain [18]. In other studies, a similar strategy was used to successfully attach various viral antigens, including porcine circovirus type two cap protein [15] and porcine epidemic diarrhea virus N protein [7], to GEM particles. In our research, we focused on PRRSV purification using surface display technology.…”

Section: Discussionmentioning

confidence: 99%

“…The GEM particles, which are deprived of intact surface proteins and intracellular content [2], are characterized by improved activity, stability and preservation. Another advantage is that GEM particles reduce the risk of dispersion of recombinant DNA into the environment [15]. One previously reported protein anchor for surface display is the lysin motif (LysM).…”

Section: Introductionmentioning

confidence: 99%

Surface-displayed porcine reproductive and respiratory syndrome virus from cell culture onto gram-positive enhancer matrix particles

Qiao

Chen

et al. 2018

Journal of Industrial Microbiology and Biotechnology

View full text Add to dashboard Cite

Vaccine immunization is now one of the most effective ways to control porcine reproductive and respiratory syndrome virus (PRRSV) infection. Impurity is one of the main factors affecting vaccine safety and efficacy. Here we present a novel innovative PRRSV purification approach based on surface display technology. First, a bifunctional protein PA-GRFT (protein anchor-griffithsin), the crucial factor in the purification process, was successfully produced in Escherichia coli yielding 80 mg/L of broth culture. Then PRRSV purification was performed by incubation of PA-GRFT with PRRSV and gram-positive enhancer matrix (GEM) particles, followed by centrifugation to collect virions loaded onto GEM particles. Our results showed that most of the bulk impurities had been removed, and PA-GRFT could capture PRRSV onto GEM particles. Our lactic acid bacteria-based purification method, which is promising as ease of operation, low cost and easy to scale-up, may represent a candidate method for the large-scale purification of this virus for vaccine production.

show abstract

Immunogenicity and immunoprotection of porcine circovirus type 2 (PCV2) Cap protein displayed by Lactococcus lactis

Cited by 35 publications

References 42 publications

The epidemiology, molecular characterization and clinical pathology of circovirus infections in pigeons – current knowledge

The epidemiology, molecular characterization and clinical pathology of circovirus infections in pigeons – current knowledge

Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice

Surface-displayed porcine reproductive and respiratory syndrome virus from cell culture onto gram-positive enhancer matrix particles

Contact Info

Product

Resources

About